AVECHO BIOTECHNOLOGY LIMITED - Announcements

Market Cap $12.67M Add to my watchlist

Healthcare

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company... Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM. More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Combining science, nature and human compassion, Little Green Pharma (ASX:LGP) are committed to improving the quality of life for sufferers of debilitating chronic conditions. NEWS: Little Green Pharma shares surge as Germany legalises Cannabis.

Announcements

Filter Results

All Price Sensitive Only

AVE	Avecho commences Phase III insomnia trial	PRICE SENSITIVE	26/03/24	202.98KB	Share
AVE	Avecho to present at NWR Virtual Healthcare Conference		18/03/24	87.99KB	Share
AVE	Avecho meets TGA ahead of Phase III Clinical Trial	PRICE SENSITIVE	14/03/24	67.34KB	Share
AVE	AVE receives final ethics approval for Phase III CBD trial	PRICE SENSITIVE	07/03/24	74.51KB	Share
AVE	Appendix 4G and Corporate Governance Statement		29/02/24	574KB	Share
AVE	Appendix 4E and Annual Report 31 December 2023	PRICE SENSITIVE	29/02/24	1.4MB	Share
AVE	December 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	31/01/24	299.59KB	Share
AVE	Expiry of Quoted Options		28/11/23	241.34KB	Share
AVE	Change of Director's Interest Notice x2		23/11/23	390.32KB	Share
AVE	Application for quotation of securities - AVE		22/11/23	30.11KB	Share
AVE	2023 General Meeting Results		09/11/23	473.79KB	Share
AVE	CEO Presentation		09/11/23	19.94MB	Share
AVE	September 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	31/10/23	495.04KB	Share
AVE	Investor Presentation		13/10/23	1.2MB	Share
AVE	Phase III Clinical Trial Investor Webinar		11/10/23	57.35KB	Share
AVE	Notice of General Meeting/Proxy Form		09/10/23	856.3KB	Share
AVE	Application for quotation of securities - AVE		07/09/23	23.2KB	Share
AVE	Appendix 4D and Half-year Financial Report	PRICE SENSITIVE	31/08/23	1.37MB	Share
AVE	Reinstatement to Official Quotation	PRICE SENSITIVE	28/08/23	86.84KB	Share
AVE	Proposed issue of securities - AVE		28/08/23	29.46KB	Share
AVE	Proposed issue of securities - AVE		28/08/23	27.65KB	Share
AVE	Avecho raises further $6M for Phase III trial	PRICE SENSITIVE	28/08/23	91.03KB	Share
AVE	Voluntary Suspension	PRICE SENSITIVE	25/08/23	168.59KB	Share
AVE	Trading Halt	PRICE SENSITIVE	23/08/23	142.38KB	Share
AVE	June 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	25/07/23	268.38KB	Share
AVE	Update - Application for quotation of securities - AVE		28/06/23	24.22KB	Share
AVE	Application for quotation of securities - AVE		28/06/23	24.72KB	Share
AVE	AVE CBD capsule passes two-year stability milestone	PRICE SENSITIVE	22/06/23	82.85KB	Share
AVE	AVE adds TPM cannabinoid gummies to portfolio	PRICE SENSITIVE	07/06/23	86.38KB	Share
AVE	USPTO allows new TPM manufacturing patent	PRICE SENSITIVE	29/05/23	79.48KB	Share
AVE	2023 Annual General Meeting Results		23/05/23	80.21KB	Share
AVE	Chair's Address and CEO Presentation		23/05/23	1.53MB	Share
AVE	Avecho licenses TPM for use in cancer drugs	PRICE SENSITIVE	22/05/23	116.81KB	Share
AVE	Withdrawal of AGM Resolutions 5(c) and 5(d)		18/05/23	202.07KB	Share
AVE	AVE commences manufacturing for Phase III trial	PRICE SENSITIVE	17/05/23	283.12KB	Share
AVE	Change in Substantial Holding		16/05/23	421.52KB	Share
AVE	Change of Director's Interest Notice x2		10/05/23	447.29KB	Share
AVE	Top 20 Option Holders		10/05/23	31.95KB	Share
AVE	Application for quotation of securities - AVE		10/05/23	27.01KB	Share
AVE	Results of Entitlement Offer	PRICE SENSITIVE	09/05/23	132.8KB	Share
AVE	Receipt of R&D Tax Incentive	PRICE SENSITIVE	02/05/23	201.89KB	Share
AVE	March 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	28/04/23	363.87KB	Share
AVE	Notice of Annual General Meeting/Proxy Form		21/04/23	538.62KB	Share
AVE	Notice to Ineligible Foreign Shareholders		13/04/23	112.82KB	Share
AVE	Notice to Eligible Shareholders		13/04/23	133.79KB	Share
AVE	Letter to Optionholders		03/04/23	49.78KB	Share
AVE	Target Market Determination		03/04/23	145.57KB	Share
AVE	Proposed issue of securities - AVE		03/04/23	46.03KB	Share
AVE	Investor Presentation	PRICE SENSITIVE	03/04/23	1.68MB	Share
AVE	Prospectus	PRICE SENSITIVE	03/04/23	624.94KB	Share
AVE	Entitlement Offer to raise $11m for Phase 3 clinical trial	PRICE SENSITIVE	03/04/23	196.62KB	Share
AVE	Avecho to present at NWR Virtual Healthcare Conference		17/03/23	61.68KB	Share
AVE	Appendix 4G and Corporate Governance Statement		15/03/23	482.77KB	Share
AVE	Annual Report - 31 December 2022		15/03/23	1.3MB	Share
AVE	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	28/02/23	182.16KB	Share
AVE	Clinical CBD program expands with the Lambert Initiative	PRICE SENSITIVE	22/02/23	78.69KB	Share
AVE	December 2022 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	31/01/23	273.71KB	Share
AVE	Athenex submits Avecho's phytonadione to FDA pre-IND	PRICE SENSITIVE	12/01/23	238.19KB	Share
AVE	Avecho receives ethics approval for Phase III CBD trial	PRICE SENSITIVE	22/12/22	131.46KB	Share
AVE	AVE signs development agreement with Perrigo	PRICE SENSITIVE	20/12/22	269.72KB	Share
AVE	September 2022 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	28/10/22	310.85KB	Share
AVE	Increased CBD absorption in dogs vs commercial comparator	PRICE SENSITIVE	19/09/22	85.86KB	Share
AVE	Application for quotation of securities - AVE		01/09/22	24.69KB	Share
AVE	Section 708A Cleansing Statement		01/09/22	92.39KB	Share
AVE	Appendix 4D and Half-year Financial Report	PRICE SENSITIVE	29/08/22	598.88KB	Share
AVE	June 2022 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	29/07/22	176.18KB	Share
AVE	Security Class Reinstatement to Quotation- AVEO	PRICE SENSITIVE	14/07/22	86.31KB	Share
AVE	Update on Listed Options and Federal Court Application	PRICE SENSITIVE	14/07/22	239.84KB	Share
AVE	Suspension from Official Quotation - AVEO	PRICE SENSITIVE	08/06/22	148.32KB	Share
AVE	Adoption of New Constitution		30/05/22	1.24MB	Share
AVE	2022 Annual General Meeting Results		30/05/22	358.14KB	Share
AVE	Chair's Address and CEO Presentation		30/05/22	1.64MB	Share
AVE	Receipt of R&D Tax Incentive	PRICE SENSITIVE	03/05/22	92.21KB	Share
AVE	March 2022 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	29/04/22	142.17KB	Share
AVE	Notice of Annual General Meeting/Proxy Form		28/04/22	509.41KB	Share
AVE	Positive results from AVE's topical CBD pain study	PRICE SENSITIVE	29/03/22	274.68KB	Share
AVE	Dosing begins in topical CBD pain study	PRICE SENSITIVE	01/03/22	93.08KB	Share
AVE	Appendix 4G and Corporate Governance Statement		28/02/22	565.04KB	Share
AVE	Appendix 4E and Annual Report 31 December 2021	PRICE SENSITIVE	28/02/22	1.38MB	Share
AVE	AVE license agreement for US recreational cannabis market	PRICE SENSITIVE	02/02/22	203.08KB	Share
AVE	December 2021 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	31/01/22	294.5KB	Share
AVE	Application for quotation of securities - AVE		10/01/22	27.42KB	Share
AVE	Section 708A Cleansing Statement		10/01/22	171.34KB	Share
AVE	AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis	PRICE SENSITIVE	20/12/21	214.39KB	Share
AVE	Positive results from Avecho's Phase I trial of CBD soft-gel	PRICE SENSITIVE	08/12/21	122.89KB	Share
AVE	September 2021 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	29/10/21	754.33KB	Share
AVE	Topical CBD pain study with Lambert Initiative approved	PRICE SENSITIVE	21/10/21	151.27KB	Share
AVE	Dosing begins in Phase I PK trial testing CBD soft-gel	PRICE SENSITIVE	04/10/21	92.31KB	Share
AVE	Phase I clinical trial testing CBD product-enrolment begins	PRICE SENSITIVE	15/09/21	72.69KB	Share
AVE	Change of Director's Interest Notice		10/09/21	237.98KB	Share
AVE	Notification of cessation of securities - AVE		10/09/21	21.56KB	Share
AVE	Appendix 4D and Half-year Financial Report	PRICE SENSITIVE	24/08/21	921.78KB	Share
AVE	June 2021 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	27/07/21	337.74KB	Share
AVE	Application for quotation of securities - AVE		01/07/21	24.99KB	Share
AVE	Section 708A Cleansing Statement		01/07/21	58.51KB	Share
AVE	Avecho to Present New CBD Data at GCI Virtual Summit	PRICE SENSITIVE	08/06/21	1.86MB	Share
AVE	Change of Director's Interest Notice x3		31/05/21	416.47KB	Share
AVE	Appendix 3G		31/05/21	238.41KB	Share
AVE	Final Director's Interest Notice		31/05/21	220.09KB	Share
AVE	2021 Annual General Meeting Results		31/05/21	70.04KB	Share

AVE Avecho commences Phase III insomnia trial
26/03/24	PRICE SENSITIVE	202.98KB	Share
AVE Avecho to present at NWR Virtual Healthcare Conference
18/03/24		87.99KB	Share
AVE Avecho meets TGA ahead of Phase III Clinical Trial
14/03/24	PRICE SENSITIVE	67.34KB	Share
AVE AVE receives final ethics approval for Phase III CBD trial
07/03/24	PRICE SENSITIVE	74.51KB	Share
AVE Appendix 4G and Corporate Governance Statement
29/02/24		574KB	Share
AVE Appendix 4E and Annual Report 31 December 2023
29/02/24	PRICE SENSITIVE	1.4MB	Share
AVE December 2023 Quarterly Activities Report & Appendix 4C
31/01/24	PRICE SENSITIVE	299.59KB	Share
AVE Expiry of Quoted Options
28/11/23		241.34KB	Share
AVE Change of Director's Interest Notice x2
23/11/23		390.32KB	Share
AVE Application for quotation of securities - AVE
22/11/23		30.11KB	Share
AVE 2023 General Meeting Results
09/11/23		473.79KB	Share
AVE CEO Presentation
09/11/23		19.94MB	Share
AVE September 2023 Quarterly Activities Report & Appendix 4C
31/10/23	PRICE SENSITIVE	495.04KB	Share
AVE Investor Presentation
13/10/23		1.2MB	Share
AVE Phase III Clinical Trial Investor Webinar
11/10/23		57.35KB	Share
AVE Notice of General Meeting/Proxy Form
09/10/23		856.3KB	Share
AVE Application for quotation of securities - AVE
07/09/23		23.2KB	Share
AVE Appendix 4D and Half-year Financial Report
31/08/23	PRICE SENSITIVE	1.37MB	Share
AVE Reinstatement to Official Quotation
28/08/23	PRICE SENSITIVE	86.84KB	Share
AVE Proposed issue of securities - AVE
28/08/23		29.46KB	Share
AVE Proposed issue of securities - AVE
28/08/23		27.65KB	Share
AVE Avecho raises further $6M for Phase III trial
28/08/23	PRICE SENSITIVE	91.03KB	Share
AVE Voluntary Suspension
25/08/23	PRICE SENSITIVE	168.59KB	Share
AVE Trading Halt
23/08/23	PRICE SENSITIVE	142.38KB	Share
AVE June 2023 Quarterly Activities Report & Appendix 4C
25/07/23	PRICE SENSITIVE	268.38KB	Share
AVE Update - Application for quotation of securities - AVE
28/06/23		24.22KB	Share
AVE Application for quotation of securities - AVE
28/06/23		24.72KB	Share
AVE AVE CBD capsule passes two-year stability milestone
22/06/23	PRICE SENSITIVE	82.85KB	Share
AVE AVE adds TPM cannabinoid gummies to portfolio
07/06/23	PRICE SENSITIVE	86.38KB	Share
AVE USPTO allows new TPM manufacturing patent
29/05/23	PRICE SENSITIVE	79.48KB	Share
AVE 2023 Annual General Meeting Results
23/05/23		80.21KB	Share
AVE Chair's Address and CEO Presentation
23/05/23		1.53MB	Share
AVE Avecho licenses TPM for use in cancer drugs
22/05/23	PRICE SENSITIVE	116.81KB	Share
AVE Withdrawal of AGM Resolutions 5(c) and 5(d)
18/05/23		202.07KB	Share
AVE AVE commences manufacturing for Phase III trial
17/05/23	PRICE SENSITIVE	283.12KB	Share
AVE Change in Substantial Holding
16/05/23		421.52KB	Share
AVE Change of Director's Interest Notice x2
10/05/23		447.29KB	Share
AVE Top 20 Option Holders
10/05/23		31.95KB	Share
AVE Application for quotation of securities - AVE
10/05/23		27.01KB	Share
AVE Results of Entitlement Offer
09/05/23	PRICE SENSITIVE	132.8KB	Share
AVE Receipt of R&D Tax Incentive
02/05/23	PRICE SENSITIVE	201.89KB	Share
AVE March 2023 Quarterly Activities Report & Appendix 4C
28/04/23	PRICE SENSITIVE	363.87KB	Share
AVE Notice of Annual General Meeting/Proxy Form
21/04/23		538.62KB	Share
AVE Notice to Ineligible Foreign Shareholders
13/04/23		112.82KB	Share
AVE Notice to Eligible Shareholders
13/04/23		133.79KB	Share
AVE Letter to Optionholders
03/04/23		49.78KB	Share
AVE Target Market Determination
03/04/23		145.57KB	Share
AVE Proposed issue of securities - AVE
03/04/23		46.03KB	Share
AVE Investor Presentation
03/04/23	PRICE SENSITIVE	1.68MB	Share
AVE Prospectus
03/04/23	PRICE SENSITIVE	624.94KB	Share
AVE Entitlement Offer to raise $11m for Phase 3 clinical trial
03/04/23	PRICE SENSITIVE	196.62KB	Share
AVE Avecho to present at NWR Virtual Healthcare Conference
17/03/23		61.68KB	Share
AVE Appendix 4G and Corporate Governance Statement
15/03/23		482.77KB	Share
AVE Annual Report - 31 December 2022
15/03/23		1.3MB	Share
AVE Appendix 4E - Preliminary Final Report
28/02/23	PRICE SENSITIVE	182.16KB	Share
AVE Clinical CBD program expands with the Lambert Initiative
22/02/23	PRICE SENSITIVE	78.69KB	Share
AVE December 2022 Quarterly Activities Report & Appendix 4C
31/01/23	PRICE SENSITIVE	273.71KB	Share
AVE Athenex submits Avecho's phytonadione to FDA pre-IND
12/01/23	PRICE SENSITIVE	238.19KB	Share
AVE Avecho receives ethics approval for Phase III CBD trial
22/12/22	PRICE SENSITIVE	131.46KB	Share
AVE AVE signs development agreement with Perrigo
20/12/22	PRICE SENSITIVE	269.72KB	Share
AVE September 2022 Quarterly Activities Report & Appendix 4C
28/10/22	PRICE SENSITIVE	310.85KB	Share
AVE Increased CBD absorption in dogs vs commercial comparator
19/09/22	PRICE SENSITIVE	85.86KB	Share
AVE Application for quotation of securities - AVE
01/09/22		24.69KB	Share
AVE Section 708A Cleansing Statement
01/09/22		92.39KB	Share
AVE Appendix 4D and Half-year Financial Report
29/08/22	PRICE SENSITIVE	598.88KB	Share
AVE June 2022 Quarterly Activities Report & Appendix 4C
29/07/22	PRICE SENSITIVE	176.18KB	Share
AVE Security Class Reinstatement to Quotation- AVEO
14/07/22	PRICE SENSITIVE	86.31KB	Share
AVE Update on Listed Options and Federal Court Application
14/07/22	PRICE SENSITIVE	239.84KB	Share
AVE Suspension from Official Quotation - AVEO
08/06/22	PRICE SENSITIVE	148.32KB	Share
AVE Adoption of New Constitution
30/05/22		1.24MB	Share
AVE 2022 Annual General Meeting Results
30/05/22		358.14KB	Share
AVE Chair's Address and CEO Presentation
30/05/22		1.64MB	Share
AVE Receipt of R&D Tax Incentive
03/05/22	PRICE SENSITIVE	92.21KB	Share
AVE March 2022 Quarterly Activities Report & Appendix 4C
29/04/22	PRICE SENSITIVE	142.17KB	Share
AVE Notice of Annual General Meeting/Proxy Form
28/04/22		509.41KB	Share
AVE Positive results from AVE's topical CBD pain study
29/03/22	PRICE SENSITIVE	274.68KB	Share
AVE Dosing begins in topical CBD pain study
01/03/22	PRICE SENSITIVE	93.08KB	Share
AVE Appendix 4G and Corporate Governance Statement
28/02/22		565.04KB	Share
AVE Appendix 4E and Annual Report 31 December 2021
28/02/22	PRICE SENSITIVE	1.38MB	Share
AVE AVE license agreement for US recreational cannabis market
02/02/22	PRICE SENSITIVE	203.08KB	Share
AVE December 2021 Quarterly Activities Report & Appendix 4C
31/01/22	PRICE SENSITIVE	294.5KB	Share
AVE Application for quotation of securities - AVE
10/01/22		27.42KB	Share
AVE Section 708A Cleansing Statement
10/01/22		171.34KB	Share
AVE AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis
20/12/21	PRICE SENSITIVE	214.39KB	Share
AVE Positive results from Avecho's Phase I trial of CBD soft-gel
08/12/21	PRICE SENSITIVE	122.89KB	Share
AVE September 2021 Quarterly Activities Report & Appendix 4C
29/10/21	PRICE SENSITIVE	754.33KB	Share
AVE Topical CBD pain study with Lambert Initiative approved
21/10/21	PRICE SENSITIVE	151.27KB	Share
AVE Dosing begins in Phase I PK trial testing CBD soft-gel
04/10/21	PRICE SENSITIVE	92.31KB	Share
AVE Phase I clinical trial testing CBD product-enrolment begins
15/09/21	PRICE SENSITIVE	72.69KB	Share
AVE Change of Director's Interest Notice
10/09/21		237.98KB	Share
AVE Notification of cessation of securities - AVE
10/09/21		21.56KB	Share
AVE Appendix 4D and Half-year Financial Report
24/08/21	PRICE SENSITIVE	921.78KB	Share
AVE June 2021 Quarterly Activities Report & Appendix 4C
27/07/21	PRICE SENSITIVE	337.74KB	Share
AVE Application for quotation of securities - AVE
01/07/21		24.99KB	Share
AVE Section 708A Cleansing Statement
01/07/21		58.51KB	Share
AVE Avecho to Present New CBD Data at GCI Virtual Summit
08/06/21	PRICE SENSITIVE	1.86MB	Share
AVE Change of Director's Interest Notice x3
31/05/21		416.47KB	Share
AVE Appendix 3G
31/05/21		238.41KB	Share
AVE Final Director's Interest Notice
31/05/21		220.09KB	Share
AVE 2021 Annual General Meeting Results
31/05/21		70.04KB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 0.4¢		Change -0.001(20.0%)		Mkt cap ! $12.67M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$27.29K	6.824M

Buyers (Bids)

No.	Vol.	Price($)
54	66436191	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	55924941	22

View Market Depth

No.	Vol.	Price($)
54	66436191	0.004
30	81684598	0.003
16	62851510	0.002
6	8000009	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	55924941	22
0.006	25945872	17
0.007	14312721	9
0.008	5987459	6
0.009	1840000	3

Last trade - 16.10pm 19/04/2024 (20 minute delay)


Last 0.4¢		Change -0.001 ( 11.1 %)
Open	High	Low	Volume
0.4¢	0.4¢	0.4¢	1103229
Last updated 15.59pm 19/04/2024 ?

AVE (ASX) Chart

AVECHO BIOTECHNOLOGY LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories